IMPACT BIOMEDICAL INC. financial data

Symbol
IBO on NYSE
Location
Houston, TX
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 07 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 11% % 8.2%
Debt-to-equity -568% %
Return On Equity 8085% % 194599%
Return On Assets -228% % -8581%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 104,621,231 shares 809%
Common Stock, Shares, Outstanding 12,185,412 shares 5.9%
Common Stock, Value, Issued $12,000 USD 9.1%
Weighted Average Number of Shares Outstanding, Basic 12,185,412 shares 5.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $18,000 USD
Research and Development Expense $122,000 USD -90%
Selling and Marketing Expense $168,000 USD -67%
Operating Income (Loss) $29,340,000 USD -701%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $44,201,000 USD -4122%
Net Income (Loss) Attributable to Parent $44,187,000 USD -3761%
Earnings Per Share, Basic -3 USD/shares -2531%
Earnings Per Share, Diluted -3 USD/shares -2287%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $12,000 USD -100%
Accounts Receivable, after Allowance for Credit Loss, Current $15,000 USD
Inventory, Net $485,000 USD
Assets, Current $917,000 USD -71%
Property, Plant and Equipment, Net $13,000 USD -95%
Goodwill $25,093,000 USD 0%
Assets $18,208,000 USD -61%
Accounts Payable, Current $576,000 USD -42%
Accrued Liabilities, Current $336,000 USD 229%
Liabilities, Current $23,793,000 USD 1991%
Deferred Income Tax Liabilities, Net $3,268,000 USD 1%
Liabilities $27,061,000 USD 119%
Retained Earnings (Accumulated Deficit) $54,752,000 USD -418%
Stockholders' Equity Attributable to Parent $11,809,000 USD -138%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $8,853,000 USD -126%
Liabilities and Equity $18,208,000 USD -61%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $682,000 USD -41%
Net Cash Provided by (Used in) Investing Activities $1,000 USD
Common Stock, Shares Authorized 4,000,000,000 shares 0%
Common Stock, Shares, Issued 12,185,412 shares 5.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $681,000 USD -68200%
Deferred Tax Assets, Gross $4,416,000 USD 24%
Depreciation $1,000 USD -50%
Property, Plant and Equipment, Gross $30,000 USD -90%
Deferred Tax Assets, Operating Loss Carryforwards $2,950,000 USD 41%
Preferred Stock, Shares Issued 60,496,041 shares 0%
Preferred Stock, Shares Authorized 100,000,000 shares 0%
Additional Paid in Capital $42,871,000 USD 2.5%
Preferred Stock, Shares Outstanding 60,496,041 shares 0%
Amortization of Intangible Assets $282,000 USD 1.4%
Depreciation, Depletion and Amortization $283,000 USD 1.1%
Interest Expense $1,062,000 USD 15%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%